MYGN
Myriad Genetics, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +10.4% ·
net new positions -7.7%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 84 | -4 | 70.39M | $401.85M | +6 | −11 |
| Q1 2026 | 92 | -3 | 73.19M | $329.45M | +3 | −6 |
| Q4 2025 | 95 | 0 | 80.50M | $495.06M | — | — |
| Q3 2025 | 19 | 0 | 56.51M | $408.57M | — | — |
| Q2 2025 | 16 | 0 | 51.45M | $273.22M | +1 | −1 |
| Q1 2025 | 13 | 0 | 25.12M | $222.86M | +1 | −1 |
| Q4 2024 | 13 | -1 | 27.01M | $370.33M | — | −1 |
| Q3 2024 | 13 | +3 | 18.94M | $518.67M | +3 | — |
| Q2 2024 | 10 | — | 22.76M | $556.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.00M | -10.6% | $82.32M | 0.0% | ▼ Trim | 3 | SEC ↗ ×5 |
| 2 | State Street Global Advisors ✦ (passive) | 5.53M | — | $75.76M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 4.35M | -16.1% | $59.57M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Glenview Capital ✦ | 4.16M | +229.6% | $57.00M | 1.4% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.14M | -0.5% | $29.39M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 1.82M | +58.0% | $24.95M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | Fisher Asset Management ✦ | 905.21K | +50.2% | $12.41M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 765.24K | +1024.3% | $10.49M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 684.87K | +87.4% | $9.39M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 348.60K | -67.2% | $4.78M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 153.06K | -13.8% | $2.10M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 114.39K | +285.0% | $1.57M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 13 | T. Rowe Price ✦ | 44.09K | -18.9% | $605,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $3.13M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 200 holders, 87.60M shares, $371.14M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.